Transgene Stock

TNG

FR0005175080

Biotechnology & Medical Research

Market Closed - Euronext Paris 11:55:00 2026-09-24 EDT			5-day change	1st Jan Change
0.8100 ^EUR	-4.37%		-6.25%	-15.62%

09-08	Transgene Expands ProBioGen Partnership With Additional License	MT
09-03	Transgene jumps 20% on positive cancer vaccine data in early trial	RE

Last Transcript: Transgene

Transgene SA - Special Call

06-29

More transcripts

Analysts' recommendations: Transgene

06-25	Oddo BHF Stays Positive on Transgene
04-07	Transgene stands out following licensing agreement with NEC Bio
11-27	Oddo BHF Lowers Target Price on Transgene but Remains Upbeat
25-10-13	Transgene and BioInvent International AB Jointly Present a Poster on Transational Data and Updated Clinical Results from the Phase I Study of BT-001	CI
25-09-18	Transgene: analysts reiterate their recommendations after results

More recommendations

News in other languages: Transgene

09-24	Transgene étend sa plateforme myvac®, et s’affirme comme un acteur clé dans un domaine en pleine émergence des immunothérapies individualisées contre le cancer
09-24	Rapport Semestriel 2026
09-24	Mise à disposition du Rapport Financier Semestriel au 30 juin 2026
09-24	Bourse : Schneider lance une OPA amicale sur Shelly, la famille Arnault réorganise sa détention de LVMH
09-24	Les bonnes nouvelles économiques ne réjouissent pas tout le monde

More news

Managers and Directors: Transgene

Manager	Title	Age	Since
Alessandro Riva CEO	Chief Executive Officer	65	2023-05-31
Lucie Larguier DFI	Director of Finance/CFO	-	2024-03-26
Simone Steiner CTO	Chief Tech/Sci/R&D Officer	-	2025-04-01

Director	Title	Age	Since
Benoît Habert BRD	Director/Board Member	61	2010-07-26
Jean-Luc Bélingard BRD	Director/Board Member	76	2013-06-18
Alain Mérieux BRD	Director/Board Member	88	2006-12-31

More insiders

Transgene is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. Transgene has a portfolio of 4 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Transgene has a production site in France.

Employees

145

Sector

Biotechnology & Medical Research

Calendar

09-23 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-09-24	€0.8100	-4.37%	98,908
26-09-23	€0.8470	-0.82%	83,920
26-09-22	€0.8540	-0.12%	34,977
26-09-21	€0.8550	-0.58%	45,388
26-09-18	€0.8600	-0.46%	21,319

Real-time Euronext Paris

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.8100EUR

Average target price

1.100EUR

Spread / Average Target

+35.80%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Cap	222M 252M 209M 191M 357M 24.21B 360M 2.51B 972M 12.32B 947M 926M 40.1B	P/E 2026 *	-5.79x	P/E 2027 *	-3.68x
Enterprise Value	153M 174M 144M 131M 246M 16.66B 247M 1.73B 669M 8.48B 652M 637M 27.59B	EV / Sales 2026 *	21.2x	EV / Sales 2027 *	29.7x
Free-Float	19.4%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Euronext Paris	TNG	Real-time
CBOE	TNGp	Real-time
Boerse Muenchen	TGNA	Real-time
London S.E.	0OCQ	Delayed
OTC Markets	TRGN.F	Delayed
Deutsche Boerse AG	TGNA	Delayed
CBOE	0OCQ	Real-time
Börse Stuttgart	TGNA	Delayed

09-24	Transgene Extends its myvac® Platform, Further Establishing its Position as a Key Player in the Rapidly Emerging Individualized Cancer Immunotherapy Field	GL
09-24	2026 Half-Year Financial Report	GL
09-24	Availability of Transgene’s Half-Year Financial Report as of June 30, 2026	GL
09-08	Transgene and ProBioGen Expand Strategic Partnership with Additional License Agreement for AGE1.CR.pIX Cell Line	GL
09-02	Transgene and Nec Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature Communications	GL

1 day	-4.37%
1 week	-6.25%
Current month	+1.38%
1 month	+0.37%
3 months	+10.20%
6 months	+8.87%
Current year	-15.62%

1 week	0.81	0.86
1 month	0.78	0.97
Current year	0.7	1.03
1 year	0.7	1.5
3 years	0.53	1.71
5 years	0.53	2.99
10 years	0.53	3.79

Transgene Stock

Stocks

TNG

FR0005175080

Biotechnology & Medical Research

Valuation: Transgene

Chart: Transgene

Latest news: Transgene

Last Transcript: Transgene

Analysts' recommendations: Transgene

Press Releases: Transgene

News in other languages: Transgene

Quotes and Performance

Price Extremes

Managers and Directors: Transgene

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Annual profits - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/2/25	Compagnie Merieux Alliance SAS	Buy	Company	84,745,400	63.8367%
12/2/25	Compagnie Merieux Alliance SAS	Buy	Company	38,492,172	28.9953%
8/2/24	Compagnie Merieux Alliance SAS	Buy	Company	30,898,876	23.3562%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TRANSGENE	-4.37%	-6.25%	-27.68%	-53.71%	264M
WUXI APPTEC CO., LTD.	-3.30%	+2.97%	+54.99%	+104.15%	74.18B
ARGENX SE	-0.12%	-3.82%	+34.21%	+74.86%	59.55B
INSMED INCORPORATED	+2.71%	-1.96%	-13.79%	+364.46%	25.84B
BIONTECH SE	+0.81%	+0.61%	-0.49%	-5.14%	24.73B
GENMAB A/S	-1.05%	+1.07%	+21.45%	-10.32%	20.87B
PHARMAESSENTIA CORPORATION	-1.70%	-4.15%	+147.82%	+325.69%	15.32B
EXELIXIS, INC.	+2.15%	-0.92%	+48.93%	+169.79%	14.06B
SUMMIT THERAPEUTICS INC.	-0.43%	-7.56%	-20.10%	+775.94%	13.12B
MADRIGAL PHARMACEUTICALS, INC.	+0.04%	-3.97%	+20.23%	+234.69%	11.85B
Average	-0.53%	-0.90%	+26.56%	+198.04%	25.98B
Weighted average by Cap.	-0.72%	-0.23%	+35.09%	+160.08%

	2026 *	2027 *
Net sales	7.2M 8.19M 6.79M 6.19M 11.58M 786M 11.67M 81.45M 31.56M 400M 30.73M 30.07M 1.3B	7.2M 8.19M 6.79M 6.19M 11.58M 786M 11.67M 81.45M 31.56M 400M 30.73M 30.07M 1.3B
Net income	-38.2M -43.43M -36.01M -32.85M -61.44M -4.17B -61.92M -432M -167M -2.12B -163M -160M -6.9B	-61.6M -70.03M -58.07M -52.98M -99.08M -6.72B -99.85M -697M -270M -3.42B -263M -257M -11.13B
Net Debt	-69.2M -78.67M -65.23M -59.52M -111M -7.55B -112M -783M -303M -3.84B -295M -289M -12.51B	-7.7M -8.75M -7.26M -6.62M -12.38M -840M -12.48M -87.11M -33.75M -428M -32.87M -32.15M -1.39B